ClinicalTrials.gg
CompletedNCT00273884Updated Feb 19, 2007

Amonafide in Combination With Cytarabine in Secondary AML

A Phase 2 interventional study of Amonafide L-Malate and Cytarabine in Acute Myeloid Leukemia, sponsored by Xanthus Pharmaceuticals, Inc.. Completed at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-02-19.

Sponsored by Xanthus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Enrollment
73rd of 239
80 · median 48
Started
2005
with 9 others
Phase 2
112 of 247
21 open now
Registered
49th of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 73rd largest by enrollment of the 239 interventional ones that give a count, is one of 10 that started in 2005, is one of 112 in phase 2, and was the 49th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

Read the detailed description

This is a two-stage, open-label, phase 2, multicenter study of amonafide L-malate in combination with standard-dose cytarabine in subjects with secondary AML.

Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. In three phase I clinical trials, amonafide demonstrated anti-leukemic activity, both as monotherapy and in combination with cytarabine. This protocol is designed to further assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

The duration of the study is approximately 42 months: enrollment approximately 18 months and subject duration up to 24 months

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML
  • Secondary AML
  • Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic diagnosis of AML (≥20% blasts of myeloid lineage in bone marrow), with FAB classification other than M3, secondary to either:

    1. Known and documented exposure to prior leukemogenic chemotherapy or radiotherapy, OR
    2. Diagnosis of MDS for ≥3 months prior to study entry (prior BM slides documenting MDS must be available for central pathology review).
  • Age 18 years or older.
  • performance status ≤2.
  • No prior induction chemotherapy for AML; at least 4 weeks since completion of prior chemotherapy for MDS. (Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy).
  • Fertile and sexually active men and women must use effective throughout study. Women of must have a negative pregnancy test.
  • ≥50% by MUGA or ECHO.
  • Adequate renal function: serum creatinine ≤1.5 x .
  • Adequate hepatic function: total serum ≤1.5 x ULN as well as serum and ALT ≤1.5 x ULN.
  • Subject must be able to participate fully in all aspects of the trial.
  • Subject must give voluntary, written consent and HIPAA authorization (US only).

Exclusion criteria

Exclusion Criteria:

  • Histologic diagnosis of FAB M3 AML (acute promyelocytic leukemia).
  • Clinically active CNS leukemia.
  • Known to be positive.
  • Prior induction chemotherapy for AML.
  • Known active or C or other active liver disease.
  • Any major surgery or radiation therapy within 4 weeks prior to study entry.
  • Prior cytotoxic chemotherapy within 4 weeks prior to study entry.(Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy).
  • Persistent chronic non-hematologic toxicity from prior chemotherapy (other than alopecia) that is > than grade 1.
  • Serious concomitant illness (e.g., active pulmonary infection, unstable angina or myocardial infarction within 3 months of study entry, congestive heart failure ≥AHA class 2, stroke within 3 months prior to study entry, uncontrolled hypertension, uncontrolled diabetes, actively bleeding gastric ulcer, etc.).
  • Women who are pregnant or lactating.
  • History of allergic reactions attributed to compounds similar to amonafide or cytarabine.
  • Prior enrollment on this trial.
  • Any other known condition (familial, sociological, or geographic) or behavior (including substance abuse, psychological or psychiatric illness), which in the investigator's opinion would make the subject a poor candidate for this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants

Interventions

06

What researchers measure

Primary outcomes

  1. - To determine the rate of complete remission with or without complete hematopoietic recovery (CR + CRi).

Secondary outcomes

  1. Determine the median duration of complete remission with or without complete hematopoietic recovery (CR or CRi)

  2. Determine the proportion of subjects remaining in complete remission (CR +CRi) at 6 months, at 12 months and at 18 months

  3. Determine the median duration of overall survival (OS)

  4. Correlate clinical responses and duration of responses with specific cytogenetic abnormalities

  5. Define the population pharmacokinetic (PK) profile of amonafide and its metabolites when administered as an intravenous infusion daily x 5 days in combination with a standard-dose of cytarabine

  6. Define the safety profile and confirm the acceptability of amonafide and cytarabine

  7. Correlate PK exposure of amonafide and acetylation of amonafide with safety and efficacy assessments in individual subjects

07

Study locations

21 sites
  • University of Alabama at Birmingham Comprehensive Cancer Center
    Birmingham, Alabama 35294-3300, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UCLA Medical Center
    Los Angeles, California 90024, United States
  • Scripps Cancer Center
    San Diego, California 92121, United States
  • University of Colorado Health Sciences Center, Anschutz Cancer Center
    Aurora, Colorado 80010, United States
  • University of Florida Health Science Center
    Gainesville, Florida 32610-0277, United States
  • Northwestern University, Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • St. Francis Cancer Research Foundation (formerly Indiana Oncology Hematology Consultants and American Health Network of Indiana LLC, Oncology Division)
    Indianapolis, Indiana 46202, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-0848, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 98198 7835, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 75246, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • MUSC - Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • West Virginia University Medical Center
    Morgantown, West Virginia 26506-9162, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 4E3, Canada
  • London Regional Cancer Program, London Health Science Center
    London, Ontario N6A 4L6, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2006
First posted
Jan 9, 2006
Start
Aug 2005
Completion
Apr 2009
Last update
Feb 19, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 19, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00273884
Lead sponsor
Xanthus Pharmaceuticals, Inc.
First posted
Jan 9, 2006
Start date
Aug 2005
Completion
Apr 2009
Last update
Feb 19, 2007

Study contacts

Steven Allen, MD
principal investigator · North Shore Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytarabine

Start the discussion